Kristen Petros de Guex
Overview
Explore the profile of Kristen Petros de Guex including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
31
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xie Y, Modi N, Handler D, Yu S, Rao P, Kagan L, et al.
Antimicrob Agents Chemother
. 2023 Oct;
67(11):e0093223.
PMID: 37877727
Variable pharmacokinetics of rifampin in tuberculosis (TB) treatment can lead to poor outcomes. Urine spectrophotometry is simpler and more accessible than recommended serum-based drug monitoring, but its optimal efficacy in...
2.
Petros de Guex K, Flickinger T, Mayevsky L, Zaveri H, Goncalves M, Reed H, et al.
JAMIA Open
. 2023 Sep;
6(3):ooad083.
PMID: 37732327
Objective: Latinx people comprise 30% of all new human immunodeficiency virus (HIV) infections in the United States and face many challenges to accessing and engaging with HIV care. To bridge...
3.
Thomas T, Lukumay S, Yu S, Rao P, Siemiatkowska A, Kagan L, et al.
Arch Dis Child
. 2023 May;
108(8):616-621.
PMID: 37171408
Objective: Pharmacokinetic variability drives tuberculosis (TB) treatment outcomes but measurement of serum drug concentrations for personalised dosing is inaccessible for children in TB-endemic settings. We compared rifampin urine excretion for...
4.
Ilaiwy G, Lukumay S, Augustino D, Mejan P, Bukhay R, Justine M, et al.
Am J Trop Med Hyg
. 2023 Apr;
108(6):1235-1239.
PMID: 37094782
At least a third of tuberculosis (TB) cases remain undiagnosed, disproportionately so in children and adolescents, which is hampering global elimination goals. Prolonged symptom duration presents a high-risk scenario for...
5.
Petros de Guex K, Augustino D, Mejan P, Gadiye R, Massong C, Lukumay S, et al.
Glob Public Health
. 2023 Apr;
18(1):2196569.
PMID: 37021699
Distinct from quantifying the economic sequelae of tuberculosis (TB) in adults, data are scarce regarding lived experiences of youth and their caregivers seeking and sustaining TB treatment in low income...
6.
Mpagama S, Mvungi H, Mbelele P, Semvua H, Liyoyo A, Petros de Guex K, et al.
Pilot Feasibility Stud
. 2023 Apr;
9(1):55.
PMID: 37005695
Background: Adverse drug reactions (ADRs) frequently occur in patients using second-line anti-tuberculosis medicine for treatment of multidrug resistant tuberculosis (MDR-TB). ADRs contribute to treatment interruptions which can compromise treatment response...
7.
Sturek J, Thomas T, Gorham J, Sheppard C, Raymond A, Petros de Guex K, et al.
Microbiol Spectr
. 2022 Feb;
10(1):e0256021.
PMID: 35196802
The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an unprecedented event requiring frequent adaptation to changing clinical circumstances. Convalescent immune plasma (CIP) is a...
8.
Flickinger T, Sherbuk J, Petros de Guex K, Anazco Villarreal D, Hilgart M, McManus K, et al.
Telemed Rep
. 2021 Apr;
2(1):46-55.
PMID: 33817694
Latinx people in the United States are disproportionately diagnosed with HIV and are more likely to experience worse HIV-related health outcomes. Although m-health has demonstrated success in improving HIV care,...
9.
Sturek J, Thomas T, Gorham J, Sheppard C, Raymond A, Petros de Guex K, et al.
medRxiv
. 2021 Feb;
PMID: 33619508
Rationale: The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an unprecedented event requiring rapid adaptation to changing clinical circumstances. Convalescent immune plasma (CIP) is...
10.
Mpagama S, Ezekiel M, Mbelele P, Chongolo A, Kibiki G, Petros de Guex K, et al.
BMC Public Health
. 2020 Nov;
20(1):1667.
PMID: 33160327
Background: Molecular diagnostics have revolutionized the diagnosis of multidrug resistant tuberculosis (MDR-TB). Yet in Tanzania we found delay in diagnosis with more than 70% of MDR-TB patients having a history...